Information Provided By:
Fly News Breaks for May 31, 2019
ZYNE
May 31, 2019 | 07:20 EDT
Cantor Fitzgerald analyst Charles Duncan raised his price target for Zynerba Pharmaceuticals to $22 from $12 citing his due diligence on Fragile X and the anecdotal use of CBD to alleviate symptoms for this and other pediatric orphan neurodevelopmental disorders. The analyst says he's also seen broadening interest in the medical cannabis space with the emergence of exchange traded funds possibly driving demand for the shares. Duncan reiterates an Overweight rating on Zynerba.
News For ZYNE From the Last 2 Days
There are no results for your query ZYNE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.